ClinicalTrials.Veeva

Menu

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

Columbia University logo

Columbia University

Status

Completed

Conditions

Chronic Kidney Disease
Endstage Renal Disease

Treatments

Procedure: Arteriovenous Fistula (AVF)
Procedure: Arteriovenous Graft (AVG)

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT02981706
AAAQ8223
R03AG053294 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This is a pilot, single-center, randomized trial of 90 subjects to evaluate complication rates and functional status decline in subjects age 65 years and older referred for vascular access placement. Subjects will be randomized to arteriovenous fistula (AVF) (n = 45) versus arteriovenous graft (AVG) (n = 45), placed in a vascular access monitoring protocol, and undergo measurements of functional status including gait speed, grip strength, and self-reported function over 6 months. The primary hypothesis to be tested is that AVF placement will result in a higher proportion of primary access failure as defined by a binary composite primary endpoint of an unsalvageable access or an immature access or a non-functional access measured at 6 months compared to AVG placement. In addition, the study will evaluate whether AVF placement and a greater number of access procedures will result in a greater decline in functional status as measured by the average change over 6 months in gait speed, grip strength, and self-reported function as assessed by the Disabilities in Arm, Shoulder and Hand Survey.

Full description

The elderly population is the fastest growing segment of the dialysis population. A vascular access is required to perform dialysis and current guidelines support arteriovenous fistulas (AVFs) over arteriovenous grafts (AVGs) as the preferred vascular access for dialysis. However, the preferred choice of vascular access in the elderly is unclear. Older adults have higher rates of complications from AVF placement compared to AVG placement. Placement of a dialysis access and the procedures subsequently required to achieve and maintain access functionality could result in further declines of function in this already frail population and potentially reduce quality of life. High burdens of cardiovascular disease, heterogeneous life expectancy and variable health goals may make the ideal choice of vascular access different in the elderly population than the general dialysis population.

Enrollment

20 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 65 years or older
  • Referred by nephrology provider for vascular access for hemodialysis (HD)
  • Able and willing to provide informed consent

Exclusion criteria

  • Patient is not a candidate for an AVF per surgeon
  • Congestive heart failure (CHF) as defined by ejection fraction (EF) < 20%, history of heart transplant, history of ventricular assist device
  • Known central venous stenosis
  • Metastatic cancer or active cancer receiving chemotherapy
  • Multiple Myeloma
  • Vein mapping with arterial diameter ≤ 2mm and vein diameter ≤ 2.5mm or presence of stenosis or thrombosis in the draining vein
  • arterial flow velocity of ≤ 40ml/min

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

20 participants in 2 patient groups

Arteriovenous Fistula (AVF) Group
Active Comparator group
Description:
Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
Treatment:
Procedure: Arteriovenous Fistula (AVF)
Arteriovenous Graft (AVG) Group
Active Comparator group
Description:
Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
Treatment:
Procedure: Arteriovenous Graft (AVG)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems